Skip to content

Study · In vitro (cells) · mouse · 2022

4 results

MOTS-c promotes muscle differentiation in vitro.

García-Benlloch S, Revert-Ros F, Blesa JR, Alis R

Peptides14 Jul 2022Cited by 9 (Europe PMC)

PMID35842023 (opens in a new tab)DOI10.1016/j.peptides.2022.170840 (opens in a new tab)PepBankPUB-35842023
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In human and murine muscle progenitor cells, wild-type MOTS‑c increased myotube formation, whereas the Y8F mutant peptide did not.

    In plain wordsIn lab-grown human and mouse muscle cells, MOTS‑c increased muscle fibre formation, but a mutated version did not.

    Peptide
    MOTS-c
    Outcome
    IncreaseMyotube formation
    Study

    human and mousen: not reported in source

    LHCN-M2 human and C2C12 murine muscle progenitor cells
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In both cellular models, treatment with wild-type MOTS-c peptide increased myotube formation whereas treatment with the Y8F peptide did not.
    1 context sentence
    Summary · context
    Here, we investigated the role of MOTS-c in the differentiation of human (LHCN-M2) and murine (C2C12) muscle progenitor cells. Cells were treated with peptides at the onset of differentiation or after myotubes had been formed.
  2. 02LabIn vitro (cells)Activity measurement

    In myocytes, wild-type MOTS‑c, but not the Y8F peptide, protected against the IL-6-induced reduction of nuclear myogenin staining.

    In plain wordsIn lab-grown muscle cells, MOTS‑c protected against an IL-6-caused drop in myogenin staining, but a mutated version did not.

    Peptide
    MOTS-c
    Outcome
    IncreaseNuclear myogenin staining after IL-6 challenge
    Study

    human and mousen: not reported in source

    LHCN-M2 human and C2C12 murine muscle progenitor cells
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c wild-type, but not Y8F peptide, also protected against interleukin-6 (IL-6)-induced reduction of nuclear myogenin staining in myocytes.
    1 context sentence
    Summary · context
    Here, we investigated the role of MOTS-c in the differentiation of human (LHCN-M2) and murine (C2C12) muscle progenitor cells. Cells were treated with peptides at the onset of differentiation or after myotubes had been formed.
  3. 03LabIn vitro (cells)Mechanism

    In muscle cells, MOTS‑c, but not the Y8F peptide, blocked the transcriptional activity of STAT3 induced by IL-6.

    In plain wordsIn lab-grown muscle cells, MOTS‑c blocked IL-6-driven STAT3 activity, but a mutated version did not.

    Peptide
    MOTS-c
    Outcome
    DecreaseIL-6-induced STAT3 transcriptional activity
    Study

    human and mousen: not reported in source

    LHCN-M2 human and C2C12 murine muscle progenitor cells
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c, but not the Y8F peptide, blocked the transcriptional activity of STAT3 induced by IL-6.
    1 context sentence
    Summary · context
    Here, we investigated the role of MOTS-c in the differentiation of human (LHCN-M2) and murine (C2C12) muscle progenitor cells. Cells were treated with peptides at the onset of differentiation or after myotubes had been formed.

Studies that did not test the peptide alone1

In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MOTS-c.

  1. 04Computer modelNot a test of MOTS-c aloneIn silicoMechanism

    An in silico analysis identified a putative SH2 binding motif in the YIFY region of the MOTS‑c sequence.

    In plain wordsA computer analysis predicted a binding motif in the YIFY region of the MOTS‑c sequence.

    Peptide
    MOTS-c
    Outcome
    Not applicablePutative SH2 binding motif in MOTS-c sequence
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Musculoskeletal

    Source sentences

    Summary
    We identified in silico a putative Src Homology 2 (SH2) binding motif in the YIFY region of the MOTS-c sequence

    In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MOTS-c.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.